tqb2858 + gemcitabine + cisplatin + anlotinib

This combination consists of **TQB2858** (a bifunctional monoclonal antibody targeting both PD-L1 and TGF-β), **gemcitabine** (a nucleoside analog antimetabolite chemotherapy), **cisplatin** (a platinum-based DNA crosslinking agent), and **anlotinib** (a multi-targeted tyrosine kinase inhibitor primarily targeting VEGFR, FGFR, PDGFR, and c-Kit). - **TQB2858** blocks the PD-L1 and TGF-β pathways that mediate immune evasion in tumors[3][5][7]. - **Gemcitabine** inhibits DNA synthesis, leading to apoptosis in rapidly dividing cancer cells[2][6][8]. - **Cisplatin** induces DNA crosslinking, blocking DNA replication and transcription, causing cell death[4][6]. - **Anlotinib** suppresses tumor angiogenesis and proliferation by inhibiting multiple kinase receptors (VEGFR, FGFR, PDGFR, c-Kit). This combination is being clinically investigated for use in recurrent or metastatic endometrial cancer, nasopharyngeal cancer, and may have activity in various solid tumors[1][7].

Other names

cisplatinanlotinibgemcitabine hydrochlorideTQB2858TQB-2858TQB 2858